1 minute read
Giuseppe joined NPL in 2013 and has since established a new Radiation Biology programme and broadened the scope of Medical Physics to support personalised radiotherapy treatments.
His primary research has enhanced our understanding of the effect of radiation on cells and tissues, making significant strides in cancer treatment through radiotherapy. He has introduced innovative methods to evaluate the effectiveness of novel radiation therapies, such as those involving nanoparticles and short-range radioisotopes, and offered crucial insights into how varying radiation exposures influence biological tissues. Recently Giuseppe has played a central role in international efforts to standardise microdosimetry practice and has led the UK's initiatives on traceability for preclinical dosimetry. This work has addressed the reproducibility crisis in biomedical research, led to new consultancy services at NPL, and formed the foundation for the first-ever preclinical dosimetry audit.
Giuseppe graduated in Nuclear Physics from the University of Naples (Italy) and specialised in Radiation Biology through a PhD at the Gray Cancer Institute (UK) and a postdoctoral fellowship at the Center for Radiological Research at Columbia University (NY, USA). He held a joint position as Professor of Medical Physics at the University of Surrey from 2018 to 2023.
Giuseppe has authored over 100 peer-reviewed papers and several book chapters. His contributions to science and leadership have earned him the titles of Fellow of the Institute of Physics and Engineering in Medicine (IPEM), Fellow of the Institute of Physics (IoP), and Honorary Member of the Royal College of Radiologists (RCR). He also holds visiting professorships at the University of Surrey, University College London, and Queen's University Belfast.
Giuseppe Schettino, NPL fellow, said: “I am very honoured to be named an NPL Fellow. This recognition is a testament to the collaborative efforts and innovative spirit of the teams I have worked with over the years. I look forward to continuing our work in advancing radiation biology and medical physics to improve patient outcomes in radiotherapy.”
Find out more about Giuseppe Schettino
09 Jul 2024